J Drugs Dermatol. 2022 Jun 1;21(6):630-636. doi: 10.36849/JDD.6864.
Precision medicine approaches are receiving increased attention in dermatology, including inflammatory skin diseases. In psoriasis, a precision medicine treatment paradigm could temper the rapid increase in pharmacy costs that have resulted from a tremendous expansion in the number of available biologic drug options. However, without a clear and agreed upon proof of clinical utility in a real-world setting, costly new pharmacotherapies are often burdened with barriers to coverage by payers and ultimately, routine patient care. This panel was assembled to discuss the evidence threshold required to demonstrate the clinical utility of a precision medicine diagnostic that predicts the biologic therapeutic class for treating psoriasis patients. The panel reviewed clinical utility study designs and economic impact study designs aimed at delineating net savings and waste reduction. A psoriasis biologic precision medicine test could optimize pharmacotherapy management of psoriasis patients. The consensus opinion of this panel was that positive results from the study described here would prove the clinical utility of this precision medicine test. J Drugs Dermatol. 2022;21(6):630-636. doi:10.36849/JDD.6864.
精准医学方法在皮肤病学中受到越来越多的关注，包括炎症性皮肤病。在银屑病中，精准医学治疗模式可以控制由于可用生物药物选择数量的巨大增加而导致的药房成本的快速增长。然而，如果在真实环境中没有明确和一致的临床实用性证据，昂贵的新药物治疗方法往往会受到支付者覆盖范围的障碍的影响，最终影响常规患者护理。该小组聚集在一起讨论了证明预测治疗银屑病患者的生物治疗类别的精准医学诊断的临床实用性所需的证据阈值。该小组审查了旨在阐明净节省和减少浪费的临床实用性研究设计和经济影响研究设计。一种银屑病生物精准医学检测方法可以优化银屑病患者的药物治疗管理。该小组的共识意见是，这里描述的研究的阳性结果将证明这种精准医学检测的临床实用性。J 皮肤病药物治疗杂志。2022;21(6):630-636. doi:10.36849/JDD.6864.
